Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study for the effects of vildagliptin in combination with metformin on vascular endothelial function and systemic metabolism in patients with type 2 diabetes; multicenter, prospective, randomized, open-label, parallel group comparison

Trial Profile

Study for the effects of vildagliptin in combination with metformin on vascular endothelial function and systemic metabolism in patients with type 2 diabetes; multicenter, prospective, randomized, open-label, parallel group comparison

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vildagliptin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 15 Sep 2017 Primary endpoint (Flow-mediated dilation) has not been met as per the results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 18 Jan 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top